Investing.com - Kymera Therapeutics Inc , (NASDAQ:KYMR) a clinical-stage biopharmaceutical firm specializing in the development of novel small molecule medicines using targeted protein degradation (TPD), surged 23.7% on Tuesday following a significant announcement. After an Independent Data Review Committee examined the preliminary safety and efficacy data of KT-474, pharmaceutical giant Sanofi (EPA:SASY) has indicated its intention to expand the ongoing Phase 2 trials for Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD). This move is expected to expedite the progression towards pivotal studies. Nello Mainolfi, PhD, Founder, President, and CEO of Kymera Therapeutics, expressed enthusiasm, noting, “This expansion, supported by the results of the interim analysis, is intended to accelerate overall timelines and inform future registrational trials. We look forward to sharing further information as it is available, including trial designs and updated timing for the expanded Phase 2 data readouts.” ⚠️Stay up to date with the latest company news using InvestingPro! Our Summer Sale is now on, click here to save over 50%!⚠️ Analysts from Truist and Stifel also responded positively to the news. Truist analysts stated that the Phase 2 HS/AD expansion of KT-474 after the interim analysis bodes well for the program, reiterating a 'Buy' stance. Meanwhile, Stifel analysts suggested that the update strongly indicates that KT-474 has demonstrated an efficacy signal with clean early safety in more than one disease. This should enhance the value for this asset and Kymera's co-co opt-in. Related Articles Kymera Therapeutics soars as Sanofi expands phase 2 trials After-hours movers: SMART Global, Chipotle Mexican Grill, LegalZoom and more UPS appoints insider Brian Dykes new CFO
Kymera Therapeutics soars as Sanofi expands phase 2 trials
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...